asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
pharma · Acute Ischemic Stroke · Chronic Kidney Disease · DMAC
DiaMedica Therapeutics
DiaMedica Therapeutics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Minneapolis, USA HQ
45 Employees
Public company Type
DMAC · NYSE Ticker
Company details
- Status
- Public
- HQ
- Minneapolis, USA
- Employees
- 45
- Programs
- 8
- Drugs
- 7
- Patents
- 9
DiaMedica Therapeutics pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
DiaMedica Therapeutics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to DiaMedica Therapeutics in public FDA and regional records.
-
Development asset linked to DiaMedica Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
orlistat
Alimentary tract and metabolism (A08)US regulatory status: approved. Molecular target: Gastric triacylglycerol lipase.
- Target
- Gastric triacylglycerol lipase
- Mechanism
- Pancreatic lipase inhibitor
-
Development asset linked to DiaMedica Therapeutics in public FDA and regional records.
-
Development asset linked to DiaMedica Therapeutics in public FDA and regional records.